CervoMed Inc. (CRVO) shareholders
Close on Nov 17, 2026Market cap $22.68MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Boger Joshua S | 2,204,143 | 20.00% | 13D (active) amendment | Jun 11, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.53%) | 1,592,863 | 9.53% | 13G (passive) | Jun 30, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (8.60%), Rajeev Shah (8.60%) and 1 more | 1,266,143 | 8.60% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 1,026,937 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 916,063 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Woodline Partners LP | 688,987 | 5.10% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRVO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Woodline Partners LP | 688,987 | 4.56% | $2.14M | New | 0.01% |
| Vanguard Capital Management LLC | 316,202 | 2.09% | $980.23K | – | 0.00% |
| Sabby Management, LLC | 248,880 | 1.65% | $771.53K | New | 0.70% |
| Geode Capital Management, LLC | 66,923 | 0.44% | $207.52K | −7,448 | 0.00% |
| BlackRock, Inc. | 53,845 | 0.36% | $166.92K | +2,185 | 0.00% |
| Byrne Asset Management LLC | 51,250 | 0.34% | $158.88K | +36,550 | 0.09% |
| Citizens Financial Group Inc/Ri | 37,477 | 0.25% | $116.18K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 36,151 | 0.24% | $112.07K | – | 0.00% |
| Jane Street Group, LLC | 32,231 | 0.21% | $99.92K | +13,985 | 0.00% |
| Thompson Davis & Co., Inc. | 29,750 | 0.20% | $92.23K | +19,750 | 0.06% |
| Savvy Advisors, Inc. | 25,922 | 0.17% | $80.36K | – | 0.00% |
| Virtu Financial LLC | 24,093 | 0.16% | $75.00K | New | 0.00% |
| State Street Corp | 20,527 | 0.14% | $63.63K | – | 0.00% |
| Cetera Investment Advisers | 19,622 | 0.13% | $60.83K | −7,715 | 0.00% |
| Summit Financial, LLC | 18,140 | 0.12% | $56.23K | New | 0.00% |
| Russell Investments Group, Ltd. | 15,363 | 0.10% | $47.63K | −727 | 0.00% |
| Northern Trust Corp | 13,318 | 0.09% | $41.29K | −16,726 | 0.00% |
| Morgan Stanley | 12,699 | 0.08% | $39.37K | −727,193 | 0.00% |
| HighTower Advisors, LLC | 11,919 | 0.08% | $36.95K | +654 | 0.00% |
| FMR LLC | 10,538 | 0.07% | $32.67K | −502 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 37 | 2M | 11.6% | 7 / 9 | 8 / 5 | 1M | 1M |
| Q1 2026 | 36 | 2M | 11.7% | 6 / 10 | 6 / 17 | 1M | 1M |
| Q4 2025 | 48 | 2M | 14.6% | 9 / 11 | 16 / 6 | 0M | 0M |
| Q3 2025 | 45 | 2M | 14.1% | 13 / 7 | 16 / 12 | 0M | 0M |
| Q2 2025 | 45 | 2M | 14.4% | 11 / 7 | 18 / 14 | 0M | 1M |
| Q1 2025 | 48 | 2M | 15.1% | 11 / 14 | 13 / 11 | 1M | 0M |
| Q4 2024 | 49 | 1M | 9.8% | 15 / 13 | 10 / 16 | 0M | 2M |
| Q3 2024 | 50 | 4M | 23.2% | 16 / 12 | 10 / 3 | 1M | 0M |
| Q2 2024 | 38 | 3M | 22.8% | 20 / 7 | 3 / 2 | 1M | 0M |
| Q1 2024 | 20 | 3M | 16.6% | 9 / 6 | 1 / 1 | 2M | 0M |
| Q4 2023 | 12 | 0M | 2.2% | 2 / 3 | 2 / 2 | 0M | 0M |
| Q3 2023 | 12 | 0M | 2.4% | 12 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
12 funds held CRVO in Q1 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CRVO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 250,174 | 1.65% | $775.54K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 66,028 | 0.44% | $204.69K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 37,241 | 0.25% | $115.82K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 19,545 | 0.13% | $60.59K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 9,020 | 0.06% | $28.05K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 8,992 | 0.06% | $27.97K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 7,411 | 0.05% | $23.05K | 0.00% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 3,281 | 0.02% | $10.20K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,068 | 0.01% | $3.31K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John J. Alam | CEO & President, Director, 10% owner | 1,496,578 | 9.90% | Jun 10, 2026 |
| Matthew Winton | Chief Commercial and Business | 15,000 | 0.10% | Oct 23, 2026 |
| Rosch Mark De | EVP, RA and GA and PgM | – | – | Oct 23, 2026 |
| Kelly Blackburn | EVP, Clinical Development | 13,674 | 0.09% | Oct 23, 2026 |
| William Robert Elder | CFO, GC & Secretary | 12,500 | 0.08% | Feb 13, 2026 |
| Robert Joseph Cobuzzi Jr. | Chief Operating Officer | 1,616 | 0.01% | Feb 14, 2025 |
| Joshua S. Boger | Director, 10% owner | 2,012,682 | 13.31% | Jun 15, 2026 |
| Frank Zavrl | Director | 353,009 | 2.33% | Jun 10, 2026 |
| Jane H. Hollingsworth | Director | 943 | 0.01% | Jun 10, 2026 |
| Jeffrey V. Poulton | Director | – | – | Jun 10, 2026 |
| Marwan Sabbagh | Director | – | – | Jun 10, 2026 |
| David Quigley | Director | – | – | Jun 10, 2026 |
| Sylvie Gregoire | Director, 10% owner | 1,496,578 | 9.90% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua S. Boger Director, 10% owner | Jun 11, 2026 | Buy | +955,414 | $3.14 | $3.00M | 1,795,865 |
| Matthew Winton Chief Commercial and Business | Nov 18, 2025 | Buy | +1,500 | $7.95 | $11.93K | 15,000 |
| William Robert Elder CFO, GC & Secretary | Nov 18, 2025 | Buy | +2,500 | $8.32 | $20.80K | 12,500 |
| Matthew Winton Chief Commercial and Business | Nov 17, 2025 | Buy | +3,500 | $8.43 | $29.51K | 13,500 |
| John J. Alam CEO & President, Director, 10% owner | Nov 17, 2025 | Buy | +10,793 | $8.46 | $91.31K | 12,500 |
| John J. Alam CEO & President, Director, 10% owner | Nov 17, 2025 | Buy | +10,807 | $8.46 | $91.43K | 1,484,078 |
| William Robert Elder CFO, GC & Secretary | Nov 17, 2025 | Buy | +1,000 | $8.45 | $8.45K | 10,000 |
| Sylvie Gregoire Director, 10% owner | Nov 17, 2025 | Buy | +10,807 | $8.46 | $91.43K | 12,500 |
| Sylvie Gregoire Director, 10% owner | Nov 17, 2025 | Buy | +10,793 | $8.46 | $91.31K | 1,484,078 |
| Matthew Winton Chief Commercial and Business | Nov 14, 2025 | Buy | +10,000 | $7.57 | $75.70K | 10,000 |
| John J. Alam CEO & President, Director, 10% owner | Nov 14, 2025 | Buy | +1,693 | $7.55 | $12.78K | 1,473,271 |
| John J. Alam CEO & President, Director, 10% owner | Nov 14, 2025 | Buy | +1,707 | $7.57 | $12.92K | 1,707 |
| Sylvie Gregoire Director, 10% owner | Nov 14, 2025 | Buy | +1,707 | $7.57 | $12.92K | 1,473,285 |
| Sylvie Gregoire Director, 10% owner | Nov 14, 2025 | Buy | +1,693 | $7.55 | $12.78K | 1,693 |
| John J. Alam CEO & President, Director, 10% owner | Nov 13, 2025 | Buy | +4,447 | $7.51 | $33.40K | 1,471,578 |
| Sylvie Gregoire Director, 10% owner | Nov 13, 2025 | Buy | +4,447 | $7.51 | $33.40K | 1,471,578 |
| John J. Alam CEO & President, Director, 10% owner | Nov 12, 2025 | Buy | +5,553 | $7.35 | $40.81K | 1,467,131 |
| William Robert Elder CFO, GC & Secretary | Nov 12, 2025 | Buy | +3,500 | $7.44 | $26.04K | 9,000 |
| Sylvie Gregoire Director, 10% owner | Nov 12, 2025 | Buy | +5,553 | $7.35 | $40.81K | 1,467,131 |
| William Robert Elder CFO, GC & Secretary | May 14, 2025 | Buy | +4,233 | $8.46 | $35.81K | 5,500 |
| William Robert Elder CFO & GC | Aug 27, 2024 | Buy | +1,000 | $18.16 | $18.16K | 1,267 |
| Joshua S. Boger Director, 10% owner | Feb 26, 2024 | Sale | −36 | – | – | 840,451 |
| Joshua S. Boger Director, 10% owner | Feb 26, 2024 | Option exercise | +495,995 | – | – | 840,487 |
| Sylvie Gregoire Director, 10% owner | Nov 9, 2023 | Gift | −10,000 | – | – | 732,039 |
| John J. Alam CEO & President, Director, 10% owner | Nov 9, 2023 | Gift | −12,500 | – | – | 729,539 |
| Jane H. Hollingsworth Director | Aug 31, 2023 | Option exercise | +122 | – | – | 943 |
| Jane H. Hollingsworth Director | Aug 31, 2023 | Returned to company | −45 | – | – | 898 |
| Diana M. Lanchoney Director | Jun 30, 2023 | Returned to company | −85 | – | – | 294 |
| Diana M. Lanchoney Director | Jun 30, 2023 | Option exercise | +232 | – | – | 379 |
| Jane H. Hollingsworth Director | May 31, 2023 | Returned to company | −68 | – | – | 1,231 |
| Jane H. Hollingsworth Director | May 31, 2023 | Option exercise | +183 | – | – | 1,299 |
| Diana M. Lanchoney Director | Mar 31, 2023 | Option exercise | +232 | – | – | 232 |
| Diana M. Lanchoney Director | Mar 31, 2023 | Returned to company | −85 | – | – | 147 |
| Jane H. Hollingsworth Director | Feb 28, 2023 | Returned to company | −68 | – | – | 1,116 |
| Jane H. Hollingsworth Director | Feb 28, 2023 | Option exercise | +183 | – | – | 1,184 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Jan 31, 2023 | Returned to company | −121 | – | – | 1,616 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Jan 31, 2023 | Option exercise | +327 | – | – | 1,737 |
| Jane H. Hollingsworth Director | Nov 30, 2022 | Option exercise | +183 | – | – | 1,069 |
| Jane H. Hollingsworth Director | Nov 30, 2022 | Returned to company | −68 | – | – | 1,001 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Oct 31, 2022 | Returned to company | −121 | – | – | 1,410 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Oct 31, 2022 | Option exercise | +327 | – | – | 1,531 |
| Jane H. Hollingsworth Director | Aug 31, 2022 | Option exercise | +183 | – | – | 954 |
| Jane H. Hollingsworth Director | Aug 31, 2022 | Returned to company | −67 | – | – | 886 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Aug 1, 2022 | Returned to company | −121 | – | – | 1,204 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Aug 1, 2022 | Option exercise | +327 | – | – | 1,325 |
| Jane H. Hollingsworth Director | May 31, 2022 | Option exercise | +183 | – | – | 838 |
| Jane H. Hollingsworth Director | May 31, 2022 | Returned to company | −67 | – | – | 771 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | May 2, 2022 | Option exercise | +327 | – | – | 1,119 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | May 2, 2022 | Returned to company | −121 | – | – | 998 |
| William Robert Elder GC & Secretary | Apr 18, 2022 | Conversion | +100 | $25.00 | $2.50K | 400 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Apr 18, 2022 | Conversion | +100 | $25.00 | $2.50K | 792 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Jan 31, 2022 | Returned to company | −6,049 | – | – | 34,602 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Jan 31, 2022 | Option exercise | +16,350 | – | – | 40,651 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Nov 1, 2021 | Option exercise | +16,350 | – | – | 30,350 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Nov 1, 2021 | Returned to company | −6,049 | – | – | 24,301 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Nov 1, 2021 | Option exercise | +16,350 | – | – | 30,350 |
| Jane H. Hollingsworth Director | May 13, 2021 | Buy | +32,786 | $0.61 | $20.00K | 32,786 |
| William Robert Elder GC & Secretary | Nov 17, 2020 | Buy | +5,000 | $0.63 | $3.15K | 15,000 |
| William Robert Elder GC & Secretary | Nov 16, 2020 | Buy | +10,000 | $0.67 | $6.70K | 10,000 |
| Robert Joseph Cobuzzi Jr. President & CEO, Director | Nov 16, 2020 | Buy | +14,000 | $0.66 | $9.24K | 14,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CervoMed's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,009 shares on Sep 3, 2026 over the last 90 days.
See a number that looks wrong?